Building an explanatory model for snakebite envenoming care in the Brazilian Amazon from the indigenous caregivers' perspective.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
28
12
2022
accepted:
14
02
2023
revised:
28
03
2023
medline:
30
3
2023
pubmed:
11
3
2023
entrez:
10
3
2023
Statut:
epublish
Résumé
In the Brazilian Amazon, snakebite envenomings (SBE) disproportionately affect indigenous peoples. Communication between indigenous and biomedical health sectors in regards to SBEs has never been explored in this region. This study aims to build an explanatory model (EM) of the indigenous healthcare domain for SBE patients from the perspective of the indigenous caregivers. This is a qualitative study involving in-depth interviews of eight indigenous caregivers who are representatives of the Tikuna, Kokama and Kambeba ethnic groups, in the Alto Solimões River, western Brazilian Amazon. Data analysis was carried out via deductive thematic analysis. A framework was built containing the explanations based on three explanatory model (EM) components: etiology, course of sickness, and treatment. To indigenous caregivers, snakes are enemies and present conscience and intention. Snakebites have a natural or a supernatural cause, the last being more difficult to prevent and treat. Use of ayahuasca tea is a strategy used by some caregivers to identify the underlying cause of the SBE. Severe or lethal SBEs are understood as having been triggered by sorcery. Treatment is characterized by four components: i) immediate self-care; ii) first care in the village, mostly including tobacco smoking, chants and prayers, combined with the intake of animal bile and emetic plants; iii) a stay in a hospital, to receive antivenom and other treatments; iv) care in the village after hospital discharge, which is a phase of re-establishment of well-being and reintroduction into social life, using tobacco smoking, massages and compresses to the affected limb, and teas of bitter plants. Dietary taboos and behavioral interdictions (avoiding contact with menstruating and pregnant women) prevent complications, relapses, and death, and must be performed up to three months after the snakebite. Caregivers are in favor of antivenom treatment in indigenous areas. There is a potential for articulation between different healthcare sectors to improve the management of SBEs in the Amazon region, and the aim is to decentralize antivenom treatment so that it occurs in indigenous health centers with the active participation of the indigenous caregivers.
Sections du résumé
BACKGROUND
In the Brazilian Amazon, snakebite envenomings (SBE) disproportionately affect indigenous peoples. Communication between indigenous and biomedical health sectors in regards to SBEs has never been explored in this region. This study aims to build an explanatory model (EM) of the indigenous healthcare domain for SBE patients from the perspective of the indigenous caregivers.
METHODOLOGY/PRINCIPAL FINDINGS
This is a qualitative study involving in-depth interviews of eight indigenous caregivers who are representatives of the Tikuna, Kokama and Kambeba ethnic groups, in the Alto Solimões River, western Brazilian Amazon. Data analysis was carried out via deductive thematic analysis. A framework was built containing the explanations based on three explanatory model (EM) components: etiology, course of sickness, and treatment. To indigenous caregivers, snakes are enemies and present conscience and intention. Snakebites have a natural or a supernatural cause, the last being more difficult to prevent and treat. Use of ayahuasca tea is a strategy used by some caregivers to identify the underlying cause of the SBE. Severe or lethal SBEs are understood as having been triggered by sorcery. Treatment is characterized by four components: i) immediate self-care; ii) first care in the village, mostly including tobacco smoking, chants and prayers, combined with the intake of animal bile and emetic plants; iii) a stay in a hospital, to receive antivenom and other treatments; iv) care in the village after hospital discharge, which is a phase of re-establishment of well-being and reintroduction into social life, using tobacco smoking, massages and compresses to the affected limb, and teas of bitter plants. Dietary taboos and behavioral interdictions (avoiding contact with menstruating and pregnant women) prevent complications, relapses, and death, and must be performed up to three months after the snakebite. Caregivers are in favor of antivenom treatment in indigenous areas.
CONCLUSIONS/SIGNIFICANCE
There is a potential for articulation between different healthcare sectors to improve the management of SBEs in the Amazon region, and the aim is to decentralize antivenom treatment so that it occurs in indigenous health centers with the active participation of the indigenous caregivers.
Identifiants
pubmed: 36897928
doi: 10.1371/journal.pntd.0011172
pii: PNTD-D-22-01628
pmc: PMC10047533
doi:
Substances chimiques
Antivenins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0011172Informations de copyright
Copyright: © 2023 de Farias et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Public Health. 2018 Nov 13;18(1):1251
pubmed: 30424745
Hist Cienc Saude Manguinhos. 2007 Dec;14 Suppl:191-212
pubmed: 18783149
Toxins (Basel). 2020 Dec 05;12(12):
pubmed: 33291444
J Ethn Subst Abuse. 2023 Jan-Mar;22(1):29-44
pubmed: 33433294
Toxicon. 2018 Sep 1;151:15-23
pubmed: 29908262
Rev Esc Enferm USP. 2015 Dec;49(6):1016-26
pubmed: 27419687
PLoS Negl Trop Dis. 2021 Sep 9;15(9):e0009758
pubmed: 34499643
BMC Public Health. 2013 Jan 19;13:52
pubmed: 23331985
Int J Equity Health. 2013 Apr 03;12:23
pubmed: 23552397
Nutr J. 2013 May 28;12:69
pubmed: 23714275
PLoS Negl Trop Dis. 2019 Feb 15;13(2):e0007171
pubmed: 30768596
Am J Hum Biol. 2008 Sep-Oct;20(5):564-71
pubmed: 18442078
Toxicon X. 2022 Sep 16;16:100137
pubmed: 36160931
PLoS Negl Trop Dis. 2021 Sep 9;15(9):e0009731
pubmed: 34499648
Nat Rev Dis Primers. 2017 Sep 14;3:17063
pubmed: 28905944
J Affect Disord. 2017 Nov;222:162-168
pubmed: 28709023
PLoS Negl Trop Dis. 2018 Feb 28;12(2):e0006299
pubmed: 29489824
Rev Panam Salud Publica. 2013 Nov;34(5):321-9
pubmed: 24553759
Int J Equity Health. 2020 Jul 31;19(1):54
pubmed: 32731874
PLoS Negl Trop Dis. 2021 Apr 16;15(4):e0009298
pubmed: 33861735
Toxins (Basel). 2022 May 28;14(6):
pubmed: 35737037
PLoS Negl Trop Dis. 2021 Mar 4;15(3):e0009245
pubmed: 33661895
Front Immunol. 2022 May 09;13:842576
pubmed: 35615352
Cad Saude Publica. 2005 Jul-Aug;21(4):1217-23
pubmed: 16021259
Salud Colect. 2017 Jul-Sep;13(3):457-470
pubmed: 29340512
PLoS One. 2020 Oct 21;15(10):e0240741
pubmed: 33085704
Rev Soc Bras Med Trop. 2015;48 Suppl 1:42-54
pubmed: 26061370
Front Immunol. 2021 Jun 08;12:659515
pubmed: 34168642